

Docket No.:11245/46604


claims are added to cover additional aspects of the invention.

These amendments and additions to the claims and the amendment to the Specification are fully supported by the specification as originally filed. No new matter has been added.

Examination of this application is respectfully requested.

Respectfully submitted,

Date: 24 April 2001


Jennifer L. King
(Reg. No. 46,828)

KENYON & KENYON
1500 K Street, N.W., Suite 700
Washington, D.C. 20005
(202) 220-4200

TELETYPE TRANSMISSION

Version With Markings To Show Changes Made

In the Specification:

The replacement paragraph for the paragraph between the title and the heading "BACKGROUND OF THE INVENTION" on page 1 differs from the original paragraph as follows:

The present application is a continuation of U.S. Patent Application Serial No. 09/374,028, filed on August 13, 1999, which is a continuation-in-part of U.S. Patent Application Serial No. 09/312,284 filed on May 14, 1999[, which is] Both Application Serial No. 09/312,284 and Application Serial No. 09/374,028 are incorporated herein by reference.

In the Claims:

The amended claims differ from the as-filed claims as follows:

1. (Amended) A method of inhibiting the growth of a refractory tumor[s] [that are stimulated] capable of stimulation by a ligand of epidermal growth factor receptor (EGFR) in a human patient[s,] which comprises [comprising] treating the human patient[s] with [an] a therapeutically effective amount of an EGFR/HER1 antagonist.
8. (Amended) A method according to claim 1 wherein the tumors are tumors of the breast, heart, lung, small intestine, colon, spleen, kidney, bladder, head and neck, ovary, prostate, brain, pancreas, skin, bone, bone marrow, blood, thymus, uterus, testicles, cervix, [and] or liver.

PCT/US2000/014060

10. (Amended) A method of inhibiting the growth of a refractory tumor[s] [that are stimulated] capable of stimulation by a ligand of epidermal growth factor receptor (EGFR) in a human patient[s,] which comprises [comprising] treating the human patient[s] with [an] a therapeutically effective amount of an EGFR/HER1 antagonist and radiation.

21. (Amended) A method according to claim 10 wherein the tumors are tumors of the breast, heart, lung, small intestine, colon, spleen, kidney, bladder, head and neck, ovary, prostate, brain, pancreas, skin, bone, bone marrow, blood, thymus, uterus, testicles, cervix, [and] or liver.

22. (Amended) A method of inhibiting the growth of a refractory tumor[s] [that are stimulated] capable of stimulation by a ligand of epidermal growth factor receptor (EGFR) in a human patient[s,] which comprises [comprising] treating the human patient[s] with [an] a therapeutically effective amount of an EGFR/HER1 antagonist and a chemotherapeutic agent.

32. (Amended) A method according to claim 22 wherein the tumors are tumors of the breast, heart, lung, small intestine, colon, spleen, kidney, bladder, head and neck, ovary, prostate, brain, pancreas, skin, bone, bone marrow, blood, thymus, uterus, testicles, cervix, [and] or liver.